Welcome to our dedicated page for Nanalysis Sci news (Ticker: NSCIF), a resource for investors and traders seeking the latest updates and insights on Nanalysis Sci stock.
Nanalysis Scientific Corp. is a leading provider of portable NMR machines and MRI technology for industrial and research applications. The company operates in two primary segments: Scientific Equipment and Security Services. In the Scientific Equipment business, Nanalysis develops and manufactures portable NMR spectrometers for laboratory and industrial markets. Their products are used in various industries and research labs globally. Recently, the company achieved significant revenue growth, introduced new innovative products, and expanded its Security Services business through a multi-million dollar government contract.
Nanalysis Scientific Corp (OTCQX: NSCIF) has reported strong preliminary Q4 2024 results, with revenue of at least $11 million and record quarterly adjusted EBITDA exceeding $1 million. This represents growth of at least $1.2MM in revenue and $1.8MM in adjusted EBITDA compared to Q4 2023.
The company achieved significant milestones including positive operating and free cash flow in 2024, record sales of 15 100MHz Benchtop NMR units in Q4, and approximately $26 million in security services revenue for 2024. The security services business improved from negative gross margins at the start of 2024 to positive double-digit margins by year-end.
Notable achievements include a co-published study with USP demonstrating Benchtop NMR efficacy for pharmaceutical quality control and two new US patents for NMR magnet and software platform technology. While achieving positive EBITDA and cash flow, after-tax Net Income remained negative for 2024.
Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) and the United States Pharmacopeia (USP) have published a study confirming the effectiveness of benchtop NMR for quality control of active pharmaceutical ingredients. The study highlights benchtop NMR's potential in the multi-billion-dollar pharmaceutical quality control market.
The technology offers several advantages including faster measurements, reduced solvent consumption, simple sample preparation, calibration-free operation, and non-destructive testing. USP's automated analysis method, USP-ID, reduces barriers to entry for benchtop NMR in pharma/biotech QC applications.
The company plans to submit multiple benchtop NMR methods to USP for acceptance, targeting expansion into global pharmacopeia jurisdictions including Europe and Japan.
Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) reported strong Q3 2024 results with 50% year-over-year revenue growth to $10.6 million. The company achieved positive EBITDA of $264K, compared to a loss of $1,354K in Q3 2023. Product sales gross margin improved to 52% from 41%, while security services margin rose to 15% from -3%. Net loss decreased to $1,644K from $6,287K in the previous year. The company saw strength in both core segments: product sales and security services, with the latter showing consistent revenue growth following complete airport service transition in Q1 2024.
Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) has scheduled its Third Quarter 2024 earnings conference call for Thursday, November 21st, 2024, at 5:00 PM ET. CEO Sean Krakiwsky and CFO Randall McRae will discuss results for the quarter ended September 30, 2024. Investors can join via phone (1-888-510-2154 or 289-819-1450 internationally) or through a webcast. A separate European Q&A session is scheduled for Friday, November 22nd at 8:30 AM ET. The webcast will be archived for 90 days, and a seven-day telephonic playback will be available.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR machines and MRI technology, announces its participation in the 17th annual LD Micro Main Event. CEO Sean Krakiwsky will present on Wednesday, October 30th at 3:00 PM PT/6:00 PM ET at the Luxe Sunset Boulevard Hotel in Los Angeles.
The event, running from October 28th to 30th, will feature approximately 150 companies presenting in half-hour increments and attending private investor meetings. Registration begins at 3:00 PM PT on the 28th, followed by keynotes and a happy hour. Presentations will run from 8:00 AM to 5:00 PM PT on the 29th and 30th.
Interested parties can register to watch the virtual presentation through the provided link to the LD Micro Main Event XVII 2024 on Sequire Events.
Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF), a leader in portable NMR machines and MRI technology for industrial and research applications, has announced its participation in the upcoming Cantech Letter Investment Conference on October 9, 2024 in Toronto, Ontario. Sean Krakiwsky, the company's CEO, will deliver an investor presentation and engage in one-on-one meetings with investors during the event.
The conference will take place at the Arcadian Loft, 8th floor, 401 Bay Street, Toronto, ON. Interested parties can register by contacting tara@cantechletter.com. Krakiwsky expressed enthusiasm about the opportunity, stating that the conference provides an excellent platform to strengthen connections within the capital markets, enhance visibility, showcase achievements, and increase the company's profile among investor communities.
Nanalysis Scientific Corp. (OTCQX: NSCIF) has reported significant growth in Q2 2024 with a 65% YoY revenue increase to $11.5M, driven by strong sales in benchtop NMR and security services, along with substantial medical imaging hardware sales. The company achieved a positive EBITDA of $414K compared to a loss of $2.4M in Q2 2023. Product sales totaled $5.4M, while service revenue soared to $5.3M, marking a 144% increase. Gross margin on product sales rose to 50%, and security services saw a 46% improvement. Significant cost reductions and efficiency improvements contributed to a net loss reduction to $2M from $4.1M. CEO Sean Krakiwsky expressed optimism for H2 2024, citing historical seasonal strength and ongoing margin improvements.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR machines and MRI technology for industrial and research applications, has announced its Second Quarter 2024 Conference Call schedule. The company will release its financial results for the quarter ended June 30, 2024, on Wednesday, August 28th, 2024. CEO Sean Krakiwsky and CFO Randall McRae will host a conference call at 5:00 P.M. Eastern Time to discuss the results. Investors can participate via phone or through a live webcast. A separate Q&A session for European investors is scheduled for Thursday, August 29th at 8:30am ET. The webcast will be archived on the company's investor relations webpage for at least 90 days, and a telephonic playback will be available for seven days after the conference call.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) announced the results of its Annual General and Special Meeting of shareholders held on June 26, 2024. All proposed resolutions were approved, including the election of directors and the appointment of Ernst & Young LLP as auditor. The number of directors was set at six, with all nominees elected for a one-year term. Shareholders voted 99.869% in favor of setting the number of directors at six, 99.056% for appointing Ernst & Young, and 98.629% for re-approving the stock option plan.
The Board welcomed Jennifer Stubbs, CFO of FLINT Corp., as a new director. Guido Cloetens stepped down, not standing for re-election. Stubbs brings extensive financial experience from various industries including energy infrastructure and real estate, notably serving at Pembina Pipeline prior to her current role at FLINT Corp.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) announced the granting of 2,237,000 stock options. Of these, 1,035,000 options were awarded to directors and officers, while 1,202,000 options were given to employees and advisors. Each option permits the purchase of one common share at $0.50 per share, with a five-year exercise window from issuance. Vesting periods range from immediate to three years.
FAQ
What is the current stock price of Nanalysis Sci (NSCIF)?
What is the market cap of Nanalysis Sci (NSCIF)?
What does Nanalysis Scientific Corp. specialize in?
In which industries are Nanalysis products used?
What recent achievements has Nanalysis Scientific Corp. made?
What are the core business segments of Nanalysis?
What sets Nanalysis Scientific Corp. apart in the market?
How can investors participate in Nanalysis updates and calls?
What financial highlights has Nanalysis recently reported?
What is the significance of the recent stock options grant by Nanalysis?
